The American Society of Clinical Oncology’s 2016 Genitourinary Cancers Symposium was held earlier this month (January 7-9) in San Francisco, California, where the brightest professionals in urology, oncology, and obstetrics and gynecology gathered to share some of the newest research on care for genitourinary cancers. Journal of Clinical Pathways hightlights the top presentations from the conference.
Cabozantinib Bests Everolimus for Treatment of Advanced Renal Cell Carcinoma
- Cabozantinib improves progression-free survival in patients with advanced renal cell carcinoma, according to an ongoing clinical trial comparing the drug with everolimus, an immunosuppressant that is the current standard treatment.
- Researchers found ia significant difference in the treatment decisions made by Caucasian and African American patients.
Digital Health Application for Real-Time Patient-Reported Outcomes During Prostate Radiotherapy
- Mobile applications that enable patients to self-report quality of life changes in real time could be useful during cancer treatment and for clinical trials.
Active Surveillance: How to Measure, Manage, and Improve
- Using proper selection criteria can better facilitate institutional adoption of active surveillance.
- Presenters revealed findings from a 10-year study analyzing the effectiveness of different treatment options for bladder cancer.
- A pathway for bladder cancer developed at City of Hope (Duarte, CA) helped to reduce patient length of stay without increasing complications or readmission rates.
- An online education system for physicians may be able to improve decision-making, quality of care, and patient outcomes.
The Impact of Subsequent Metastasis on Medical Costs in Medicare Patients with Prostate Cancer
- According to results from a study, metastasis in Medicare beneficiaries with prostate cancer can produce significant cost increases for patients and healthcare systems.
Cost-Effectiveness Analysis of Initial Management Strategies for Low-Risk Prostate Cancer
- Presenters shared the results of a multifaceted analysis of the different care strategies available to providers for the treatment of low-risk prostate cancer.
- Researchers presented data from a study to determine the best treatment for patients with high-risk prostate cancer.